Operators in the Brand Name Pharmaceutical Manufacturing industry have grappled in recent years with one of the largest waves of drug patent expirations in history. As this so-called patent cliff occurred, many blockbuster drugs lost patent exclusivity, enabling low-price generic drugs to inundate the market. As a result, many brand name pharmaceutical manufacturers have contended with intensifying competition from generic manufacturers, cutting into revenue growth. Over the five years to 2021, investments in research and development that generate a high return will occur as many pharmaceutical manufacturers strengthen their drug pipeline with orphan drugs, which typically have a smaller disease population and lower requirements for the number of patients tested during clinical trials.Pharmaceutical manufacturers develop prescription and over-the-counter products that are used to prevent or treat illnesses in humans or animals. Brand name drugs and medication have patent protection. This industry does not include nutritional supplement or cosmetic product manufacturers.
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.